Evaluation of the pharmacokinetics and the pharmacodynamics of different dry powder inhalation formulations of AZD3199 in patients with Asthma

Study identifier:D0570C00011

ClinicalTrials.gov identifier:N/A

EudraCT identifier:2011-000133-37

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 Administered via Single Inhalation Device Compared to AZD3199 Administered via Turbuhaler™ Inhaler in Patients With Asthma

Medical condition

asthma

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD3199

Sex

All

Actual Enrollment

39

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 May 2011
Primary Completion Date: 01 Feb 2012
Study Completion Date: 01 Feb 2012

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria